Beta-1 blocker improves survival of septic rats through preservation of gut barrier function

Katsuya Mori, Hiroshi Morisaki, Satoshi Yajima, Takeshi Suzuki, Akiko Ishikawa, Norihito Nakamura, Yasushi Innami, Junzo Takeda

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Objective: Since recent study demonstrated beneficial effects of β-adrenergic blocker in sepsis, we tested the hypothesis that infusion of selective β1-blocker, esmolol, improves outcome in sepsis by modulating inflammatory responses and gut barrier function. Design: Prospective randomized animal study. Setting: University research laboratory. Subjects: Male Wistar rats. Interventions: To assess the effects of esmolol infusion on survival time, 19 animals that underwent cecal ligation and perforation were randomized into control (n = 9) or esmolol (n = 10) groups, the latter of which received esmolol infusion (15 mg/kg/h) throughout the study period. In an additional 20 animals, levels of tumor necrosis factor-α (TNF-α) in both plasma and intraperitoneal fluid were measured, and mesenteric lymph nodes (MLNs) and ileum were excised for evaluation of bacterial translocation and mucosal injury at the 18-h study period. Measurements and results: Mean survival time in the esmolol group was significantly longer compared with the control group (69.5 ± 26.8 versus 28.6 ± 11.0 h). Plasma TNF-α was not detectable in either group, while intraperitoneal fluid TNF-α level was elevated in the control group but significantly depressed in the esmolol group (16.8 ± 10.7 versus 5.4 ± 7.1 pg/ml, P < 0.05). Simultaneously, the Escherichia coli positive rate of MLNs was higher (100% versus 44%, P < 0.05) and the gut mucosal injury score was elevated (4.1 ± 0.6 versus 2.8 ± 0.6, P < 0.01) in the control compared with the esmolol group. Conclusions: Beta-1 blocker therapy improves outcome in sepsis possibly through modulation of gut mucosal integrity and local inflammatory response.

Original languageEnglish
Pages (from-to)1849-1856
Number of pages8
JournalIntensive Care Medicine
Volume37
Issue number11
DOIs
Publication statusPublished - 2011 Nov

Fingerprint

Sepsis
Tumor Necrosis Factor-alpha
Lymph Nodes
Bacterial Translocation
Control Groups
Adrenergic Antagonists
Wounds and Injuries
esmolol
Ileum
Ligation
Wistar Rats
Escherichia coli
Research
Therapeutics

Keywords

  • β1-Adrenergic blocker
  • Gut barrier function
  • Inflammatory response

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Beta-1 blocker improves survival of septic rats through preservation of gut barrier function. / Mori, Katsuya; Morisaki, Hiroshi; Yajima, Satoshi; Suzuki, Takeshi; Ishikawa, Akiko; Nakamura, Norihito; Innami, Yasushi; Takeda, Junzo.

In: Intensive Care Medicine, Vol. 37, No. 11, 11.2011, p. 1849-1856.

Research output: Contribution to journalArticle

Mori, K, Morisaki, H, Yajima, S, Suzuki, T, Ishikawa, A, Nakamura, N, Innami, Y & Takeda, J 2011, 'Beta-1 blocker improves survival of septic rats through preservation of gut barrier function', Intensive Care Medicine, vol. 37, no. 11, pp. 1849-1856. https://doi.org/10.1007/s00134-011-2326-x
Mori, Katsuya ; Morisaki, Hiroshi ; Yajima, Satoshi ; Suzuki, Takeshi ; Ishikawa, Akiko ; Nakamura, Norihito ; Innami, Yasushi ; Takeda, Junzo. / Beta-1 blocker improves survival of septic rats through preservation of gut barrier function. In: Intensive Care Medicine. 2011 ; Vol. 37, No. 11. pp. 1849-1856.
@article{672ed0df8bd54cbaa05590f95d1c082a,
title = "Beta-1 blocker improves survival of septic rats through preservation of gut barrier function",
abstract = "Objective: Since recent study demonstrated beneficial effects of β-adrenergic blocker in sepsis, we tested the hypothesis that infusion of selective β1-blocker, esmolol, improves outcome in sepsis by modulating inflammatory responses and gut barrier function. Design: Prospective randomized animal study. Setting: University research laboratory. Subjects: Male Wistar rats. Interventions: To assess the effects of esmolol infusion on survival time, 19 animals that underwent cecal ligation and perforation were randomized into control (n = 9) or esmolol (n = 10) groups, the latter of which received esmolol infusion (15 mg/kg/h) throughout the study period. In an additional 20 animals, levels of tumor necrosis factor-α (TNF-α) in both plasma and intraperitoneal fluid were measured, and mesenteric lymph nodes (MLNs) and ileum were excised for evaluation of bacterial translocation and mucosal injury at the 18-h study period. Measurements and results: Mean survival time in the esmolol group was significantly longer compared with the control group (69.5 ± 26.8 versus 28.6 ± 11.0 h). Plasma TNF-α was not detectable in either group, while intraperitoneal fluid TNF-α level was elevated in the control group but significantly depressed in the esmolol group (16.8 ± 10.7 versus 5.4 ± 7.1 pg/ml, P < 0.05). Simultaneously, the Escherichia coli positive rate of MLNs was higher (100{\%} versus 44{\%}, P < 0.05) and the gut mucosal injury score was elevated (4.1 ± 0.6 versus 2.8 ± 0.6, P < 0.01) in the control compared with the esmolol group. Conclusions: Beta-1 blocker therapy improves outcome in sepsis possibly through modulation of gut mucosal integrity and local inflammatory response.",
keywords = "β1-Adrenergic blocker, Gut barrier function, Inflammatory response",
author = "Katsuya Mori and Hiroshi Morisaki and Satoshi Yajima and Takeshi Suzuki and Akiko Ishikawa and Norihito Nakamura and Yasushi Innami and Junzo Takeda",
year = "2011",
month = "11",
doi = "10.1007/s00134-011-2326-x",
language = "English",
volume = "37",
pages = "1849--1856",
journal = "Intensive Care Medicine",
issn = "0342-4642",
publisher = "Springer Verlag",
number = "11",

}

TY - JOUR

T1 - Beta-1 blocker improves survival of septic rats through preservation of gut barrier function

AU - Mori, Katsuya

AU - Morisaki, Hiroshi

AU - Yajima, Satoshi

AU - Suzuki, Takeshi

AU - Ishikawa, Akiko

AU - Nakamura, Norihito

AU - Innami, Yasushi

AU - Takeda, Junzo

PY - 2011/11

Y1 - 2011/11

N2 - Objective: Since recent study demonstrated beneficial effects of β-adrenergic blocker in sepsis, we tested the hypothesis that infusion of selective β1-blocker, esmolol, improves outcome in sepsis by modulating inflammatory responses and gut barrier function. Design: Prospective randomized animal study. Setting: University research laboratory. Subjects: Male Wistar rats. Interventions: To assess the effects of esmolol infusion on survival time, 19 animals that underwent cecal ligation and perforation were randomized into control (n = 9) or esmolol (n = 10) groups, the latter of which received esmolol infusion (15 mg/kg/h) throughout the study period. In an additional 20 animals, levels of tumor necrosis factor-α (TNF-α) in both plasma and intraperitoneal fluid were measured, and mesenteric lymph nodes (MLNs) and ileum were excised for evaluation of bacterial translocation and mucosal injury at the 18-h study period. Measurements and results: Mean survival time in the esmolol group was significantly longer compared with the control group (69.5 ± 26.8 versus 28.6 ± 11.0 h). Plasma TNF-α was not detectable in either group, while intraperitoneal fluid TNF-α level was elevated in the control group but significantly depressed in the esmolol group (16.8 ± 10.7 versus 5.4 ± 7.1 pg/ml, P < 0.05). Simultaneously, the Escherichia coli positive rate of MLNs was higher (100% versus 44%, P < 0.05) and the gut mucosal injury score was elevated (4.1 ± 0.6 versus 2.8 ± 0.6, P < 0.01) in the control compared with the esmolol group. Conclusions: Beta-1 blocker therapy improves outcome in sepsis possibly through modulation of gut mucosal integrity and local inflammatory response.

AB - Objective: Since recent study demonstrated beneficial effects of β-adrenergic blocker in sepsis, we tested the hypothesis that infusion of selective β1-blocker, esmolol, improves outcome in sepsis by modulating inflammatory responses and gut barrier function. Design: Prospective randomized animal study. Setting: University research laboratory. Subjects: Male Wistar rats. Interventions: To assess the effects of esmolol infusion on survival time, 19 animals that underwent cecal ligation and perforation were randomized into control (n = 9) or esmolol (n = 10) groups, the latter of which received esmolol infusion (15 mg/kg/h) throughout the study period. In an additional 20 animals, levels of tumor necrosis factor-α (TNF-α) in both plasma and intraperitoneal fluid were measured, and mesenteric lymph nodes (MLNs) and ileum were excised for evaluation of bacterial translocation and mucosal injury at the 18-h study period. Measurements and results: Mean survival time in the esmolol group was significantly longer compared with the control group (69.5 ± 26.8 versus 28.6 ± 11.0 h). Plasma TNF-α was not detectable in either group, while intraperitoneal fluid TNF-α level was elevated in the control group but significantly depressed in the esmolol group (16.8 ± 10.7 versus 5.4 ± 7.1 pg/ml, P < 0.05). Simultaneously, the Escherichia coli positive rate of MLNs was higher (100% versus 44%, P < 0.05) and the gut mucosal injury score was elevated (4.1 ± 0.6 versus 2.8 ± 0.6, P < 0.01) in the control compared with the esmolol group. Conclusions: Beta-1 blocker therapy improves outcome in sepsis possibly through modulation of gut mucosal integrity and local inflammatory response.

KW - β1-Adrenergic blocker

KW - Gut barrier function

KW - Inflammatory response

UR - http://www.scopus.com/inward/record.url?scp=82555167067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82555167067&partnerID=8YFLogxK

U2 - 10.1007/s00134-011-2326-x

DO - 10.1007/s00134-011-2326-x

M3 - Article

C2 - 21847651

AN - SCOPUS:82555167067

VL - 37

SP - 1849

EP - 1856

JO - Intensive Care Medicine

JF - Intensive Care Medicine

SN - 0342-4642

IS - 11

ER -